Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-HT1A dysfunction in borderline personality disorder.

M Hansenne1, W Pitchot, E Pinto

  • 1Department of Psychiatry, University of Liège, CHU Sart Tilman, Belgium.

Psychological Medicine
|August 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Tree diversity is changing across tropical Andean and Amazonian forests in response to global change.

Nature ecology & evolution·2026
Same author

Tree diversity is changing across tropical Andean and Amazonian forests in response to global change.

Nature ecology & evolution·2026
Same author

Development and validation of a highly-sensitive, quantitative LC-MS/MS assay to evaluate plasma oxytocin.

Journal of mass spectrometry and advances in the clinical lab·2025
Same author

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.

Journal of translational medicine·2025
Same author

Imaging and Interventional Management of Lymphatic Disorders.

Lymphology·2024
Same author

[Environmental crisis and mental health].

Revue medicale de Liege·2022

Borderline personality disorder (BPD) patients show reduced prolactin responses to a specific serotonin agonist, indicating impaired serotonergic function and potential links to impulsivity and suicidal behavior.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Previous studies suggest serotonergic dysfunction in borderline personality disorder (BPD).
  • Existing research used pharmacological probes with mixed effects on neurotransmitters.
  • Fenfluramine and m-CPP also affect dopamine, complicating interpretation of prior BPD serotonergic studies.

Purpose of the Study:

  • To investigate serotonergic function in BPD using a selective 5-HT1A agonist.
  • To assess prolactin (PRL) response to flesinoxan in BPD patients.
  • To compare BPD patients with healthy controls and patients with major depression.

Main Methods:

  • A flesinoxan challenge test was administered to 20 BPD inpatients and 20 healthy controls.
  • A separate group of 20 depressed inpatients was included for comparison.

Related Experiment Videos

  • Participants were matched for gender, but not age.

    • Main Results:

    • BPD patients exhibited a blunted prolactin (PRL) response compared to controls.
    • Depressed patients did not show significant differences in PRL response compared to controls.
    • BPD patients with a history of suicide attempts had lower PRL responses than those without.

    Conclusions:

    • Findings indicate significant involvement of serotonergic function in BPD.
    • Results suggest reduced 5-HT1A receptor sensitivity in BPD.
    • The study supports a link between 5-HT1A activity and suicidal behavior in BPD.